Plans announced for five new proton therapy centers across Romania, Greece, Italy, Northern Ireland, and Poland aim to expand treatment capacity for patients across Europe. The initiative builds on proton therapy’s ability to concentrate radiation dose within tumors while sparing surrounding tissue through the physical properties of proton beams. While the announcement is focused on infrastructure and access rather than a specific clinical trial result, it matters for biotech and pharmaceutical developers because proton capacity can shift treatment landscapes for oncology cohorts where combination regimens and drug-RT sequencing are under active investigation. The network growth also strengthens the pipeline of clinical referrals and imaging/biomarker sampling that often accompanies advanced radiotherapy platforms.